Hengyu Biotech offers a comprehensive, high-standard international service platform for biosafety testing aimed at global innovative drug companies. Its services include virus clearance process validation, cell bank characterization, replication-competent virus detection (RCL, RCR, rcAAV, RCA), batch release testing, CGT bioanalysis, and process residuals detection. The company’s offerings cover biologics from early development through regulatory submission and market launch. Hengyu emphasizes meeting submission requirements across China, the U.S., and Europe. Recently it completed a near ¥200 million B round, strengthening its financial position for growth. The company plans to use the proceeds to enhance its internationally compliant quality systems, expand its product line, and accelerate overseas business development.

Total raised

$28M

Funding rounds

1

Latest round

Series B

Latest activity

Mar 2024